Annual revenue rose from KRW 16 billion in 2022 to KRW 28.5 billion in 2023, a 77.6% increase, and reached KRW 33.1 billion in 2024, up 16.4%, making 2024 the largest year of 2022–2025. Revenue was KRW 33 billion in 2025, down 0.5%.
Operating profit peaked at KRW 5.61 billion in 2023, up 141.3%, then fell 35.3% to KRW 3.63 billion in 2024 and 19.5% to KRW 2.92 billion in 2025, a two-year decline. The operating margin moved from 14.5% in 2022 and 19.7% in 2023 to 10.9% in 2024 and 8.9% in 2025, so revenue held up while margins compressed.
The company attributed the 2024 profit drop to one-off costs, including clinic investment and special bonuses tied to the listing.
In 2024 higher non-operating expenses from the SPAC merger pushed the company to a net loss attributable to controlling shareholders of KRW 1.65 billion, and in 2025 those expenses normalized, returning it to a profit of KRW 2.67 billion.
Operating cash flow was KRW 1.45 billion in 2022, KRW 3.29 billion in 2023, and KRW 6.93 billion in 2024, before falling to KRW 2.03 billion in 2025. The debt ratio fell from 61.7% in 2022 to 12.7% in 2025, with total equity of KRW 33.8 billion and total liabilities of KRW 4.29 billion at end-2025.
Quarterly revenue climbed from KRW 8.56 billion in Q3 2025 to KRW 15.6 billion in Q2 2026, the highest in the filed record, before falling 12.8% to KRW 13.6 billion in Q3 2026.
Quarterly operating profit bottomed at KRW 643 million in Q4 2025 and recovered to KRW 1.91 billion in Q1 2026, KRW 2.69 billion in Q2, and KRW 2.61 billion in Q3. Net profit attributable to controlling shareholders over the last four quarters totaled KRW 7.04 billion.
One media outlet described Q2 2026 revenue as the largest quarterly sales on record, and the company attributed growth to higher supply to large existing customers and new brand and mid-sized customers.